Limei Zhao

Dr. Limei Zhao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SXShansen Xu
Shansen Xu
YCYanan Chen
Yanan Chen
YMYiyi Ma
Yiyi Ma
TLTing Liu
Ting Liu
MZMingming Zhao
Mingming Zhao
LZLimei Zhao
Limei Zhao
Valproic acid (VPA) is one of the most widely prescribed antiepileptic drugs, as VPA-induced hepatotoxicity is one of the most severe adverse reaction that can lead to death. The objective of this study was to gain an understanding of dysregulated lipid metabolism in mechanism of hepatotoxicity. Nontargeted lipidomics analysis with liquid chromatography–quadrupole-time-of-flight mass spectrometry (LC-Q-TOF/MS) was performed to explore differential lipids from the patient serum and L02 cells. Lipidomics data interpretation was augmented by gene expression analyses for the key enzymes in lipid metabolism pathways. From patient serum lipidomics, pronouncedly changed lipid species between abnormal liver function (ALF) patients and normal liver function (NLF) patients were identified. Among these lipid species, LPCs, Cers, and SMs were markedly reduced in the ALF group and showed negative relationships with liver injury severity [alanine aminotransferase (ALT) levels], while significantly increased triacylglycerols (TAG) with higher summed carbon numbers demonstrated a positive relationship with ALT levels. Regarding lipidomics in hepatic L02 cells, TAG was markedly elevated after VPA exposure, especially in TAGs with more than 53 summed carbons. Besides, gene expression analysis revealed dysregulated lipid metabolism in VPA-treated L02 cells. Peroxime proliferators-activated receptor (PPARγ) pathway played an important role in VPA-induced lipid disruption through inducing long-chain fatty acid uptake and TAG synthesis, which was also regulated by Akt pathway. Our findings present that VPA-induced lipid metabolism disruption might lead to lipotoxicity in the liver. This approach is expected to be applicable for other drug-induced toxicity assessments.

26 August 2015 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
LLLimin Liu
Limin Liu
LZLimei Zhao
Limei Zhao
QWQiuning Wang
Qiuning Wang
FQFeng Qiu
Feng Qiu
XWXiujun Wu
Xiujun Wu
YMYanan Ma
Yanan Ma

12 September 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JZJingkai Zhou
Jingkai Zhou
MLMei Liu
Mei Liu
YCYanan Chen
Yanan Chen
SXShansen Xu
Shansen Xu
YGYingjie Guo
Yingjie Guo
LZLimei Zhao
Limei Zhao


21 January 2016 in Biomedical Chromatography
Verified
Journal Article
Open access
PDF file
LZLimei Zhao
Limei Zhao
FYFan Yang
Fan Yang
MLMei Liu
Mei Liu
XSXianying Su
Xianying Su
MZMingming Zhao
Mingming Zhao
LZLimei Zhao
Limei Zhao
With the purpose of carrying out pharmacokinetic interaction studies ofnberberine (BBR) and fenofibrate (FBT), an UPLC‐MS/MS method has been developed and validated. The analytes, BBR and fenofibric acid (FBA, metabolite of FBT) and the internal standard, tetrahydropalmatine, were extracted with dichloromethane–diethyl ether (3:2, v/v) and separated on an Agilent Eclipse XDB C18 column using a mobile phase composed of acetonitrile and water. With positive ion electrospray ionization, the analytes were monitored on a triple quadrupole mass spectrometer in multiple reaction monitoring mode. Linear calibration curves were obtained over the concentration ranges of 0.1–100.0 ng/mL for BBR and 10.0–50,000.0 ng/mL for FBA. For BBR and FBA, the intra‐ and inter‐day precisions were 85.6%, and those of FBA at three concentrations of 20.0, 2500.0, 40,000.0 ng/mL were >87.9%. Consequently, the proposed method was applied to the pharmacokinetic interaction study of FBT combined with BBR after oral administration in rats and was proved to be sensitive, specific and reliable to analyze BBR and FBA in biological samples simultaneously. Copyright © 2016 John Wiley & Sons, Ltd.

4 July 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SXShansen Xu
Shansen Xu
YCYanan Chen
Yanan Chen
MZMingming Zhao
Mingming Zhao
YGYingjie Guo
Yingjie Guo
ZWZhan-You Wang
Zhan-You Wang
LZLimei Zhao
Limei Zhao